Biohaven Pharmaceutical Stock Forecast, Price & News

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

Is Biohaven Pharmaceutical a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biohaven Pharmaceutical stock.
View analyst ratings for Biohaven Pharmaceutical or view top-rated stocks.

How has Biohaven Pharmaceutical's stock price been impacted by Coronavirus?

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BHVN shares have increased by 167.8% and is now trading at $105.66.
View which stocks have been most impacted by COVID-19.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Biohaven Pharmaceutical.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) posted its earnings results on Monday, November, 8th. The company reported ($2.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.40) by $0.23. The business earned $135.74 million during the quarter, compared to analysts' expectations of $128.40 million. The business's quarterly revenue was up 668.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.27) earnings per share.
View Biohaven Pharmaceutical's earnings history.

What guidance has Biohaven Pharmaceutical issued on next quarter's earnings?

Biohaven Pharmaceutical issued an update on its third quarter 2021 earnings guidance on Wednesday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $136 million-$136 million, compared to the consensus revenue estimate of $123.69 million.

What price target have analysts set for BHVN?

11 brokers have issued 1 year price objectives for Biohaven Pharmaceutical's stock. Their forecasts range from $105.00 to $177.00. On average, they anticipate Biohaven Pharmaceutical's share price to reach $144.60 in the next twelve months. This suggests a possible upside of 36.9% from the stock's current price.
View analysts' price targets for Biohaven Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the following people:

• Vladimir Coric, Chief Executive Officer & Director
• Lisa Stocking, Director-Operations & Regulatory Affairs
• James Engelhart, Chief Financial Officer & Treasurer
• Charles Conway, Chief Scientific Officer
• Elyse Stock, Chief Medical Officer

Who are some of Biohaven Pharmaceutical's key competitors?

Some companies that are related to Biohaven Pharmaceutical include Genmab A/S (GMAB), Genmab A/S (GNMSF), Shiseido (SSDOY), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Takeda Pharmaceutical (TKPYY), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Elanco Animal Health (ELAN), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF) and Dr. Reddy's Laboratories (RDY).
View all of BHVN's competitors.

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital World Investors (9.26%), BlackRock Inc. (7.04%), Marshall Wace LLP (4.15%), Polar Capital Holdings Plc (1.92%), Bank of New York Mellon Corp (1.91%) and Alliancebernstein L.P. (1.65%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, Robert Berman and William A Jones Jr.
View institutional ownership trends for Biohaven Pharmaceutical.

Which major investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Glenview Capital Management LLC, Alliancebernstein L.P., Hood River Capital Management LLC, Wellington Management Group LLP, ARS Investment Partners LLC, BlackRock Inc., Lombard Odier Asset Management Switzerland SA, and Rhenman & Partners Asset Management AB.
View insider buying and selling activity for Biohaven Pharmaceutical or view top insider-selling stocks.

Which major investors are buying Biohaven Pharmaceutical stock?

BHVN stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Polar Capital Holdings Plc, Fisher Asset Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Voloridge Investment Management LLC, Two Sigma Investments LP, and Lord Abbett & CO. LLC.
View insider buying and selling activity for Biohaven Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $105.66.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical has a market capitalization of $6.92 billion and generates $63.63 million in revenue each year. The company earns $-766.80 million in net income (profit) each year or ($13.69) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

Biohaven Pharmaceutical employs 825 workers across the globe.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

Where are Biohaven Pharmaceutical's headquarters?

Biohaven Pharmaceutical is headquartered at 215 CHURCH STREET, NEW HAVEN CT, 06510.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at (203) 404-0410.